AIFM2 and hepatocellular carcinoma: Additionally, combining an FSP1 inhibitor with immune checkpoint inhibitors demonstrates synergistic effects in suppressing HCC growth, suggesting that targeting FSP1 may enhance the efficacy of immunotherapy [43,46].